CN108114149B - 一种蒙药苏龙嘎-4的制备方法 - Google Patents
一种蒙药苏龙嘎-4的制备方法 Download PDFInfo
- Publication number
- CN108114149B CN108114149B CN201810130334.9A CN201810130334A CN108114149B CN 108114149 B CN108114149 B CN 108114149B CN 201810130334 A CN201810130334 A CN 201810130334A CN 108114149 B CN108114149 B CN 108114149B
- Authority
- CN
- China
- Prior art keywords
- mongolian
- preparation
- drug
- volatile oil
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000000605 extraction Methods 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000008187 granular material Substances 0.000 claims abstract description 19
- 239000000341 volatile oil Substances 0.000 claims abstract description 17
- 239000004375 Dextrin Substances 0.000 claims abstract description 11
- 229920001353 Dextrin Polymers 0.000 claims abstract description 11
- 235000019425 dextrin Nutrition 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 7
- 244000233952 Polygonum bistorta Species 0.000 claims abstract description 5
- 235000014258 Polygonum bistorta Nutrition 0.000 claims abstract description 5
- 238000004821 distillation Methods 0.000 claims abstract description 3
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 239000003960 organic solvent Substances 0.000 claims abstract description 3
- 238000010298 pulverizing process Methods 0.000 claims abstract description 3
- 238000005507 spraying Methods 0.000 claims abstract description 3
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract 2
- 108010011485 Aspartame Proteins 0.000 claims description 8
- 239000000605 aspartame Substances 0.000 claims description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 8
- 229960003438 aspartame Drugs 0.000 claims description 8
- 235000010357 aspartame Nutrition 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000013355 food flavoring agent Nutrition 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 8
- 241000722953 Akebia Species 0.000 claims description 5
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 3
- 229960001462 sodium cyclamate Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 9
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 239000002552 dosage form Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 4
- 238000012216 screening Methods 0.000 abstract description 4
- 241000576429 Forsythia suspensa Species 0.000 abstract description 2
- 240000008027 Akebia quinata Species 0.000 abstract 1
- 235000007756 Akebia quinata Nutrition 0.000 abstract 1
- 238000005360 mashing Methods 0.000 abstract 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 9
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 9
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 9
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 9
- 229940074393 chlorogenic acid Drugs 0.000 description 9
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 9
- 235000001368 chlorogenic acid Nutrition 0.000 description 9
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 244000248557 Ophiopogon japonicus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- DTOUWTJYUCZJQD-UJERWXFOSA-N Forsythiaside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 DTOUWTJYUCZJQD-UJERWXFOSA-N 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229930190017 ophiopogonin Natural products 0.000 description 1
- 229930190714 ophiopogonone Natural products 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种蒙药成方新剂型的制备方法，具体涉及一种蒙药苏龙嘎‑4的制备方法，蒙药苏龙嘎‑4处方包括连翘、拳参、木通、麦冬，该制备方法包括如下步骤：A.取连翘捣碎，加水，蒸馏法提取挥发油，挥发油备用；B.连翘水溶液药渣与其余拳参、木通、麦冬三味药混合，水煎1‑3次，合并过滤，滤液浓缩得浸膏，低温干燥，粉碎，加入矫味剂和糊精，制成颗粒，干燥；C.加入所述挥发油或用有机溶剂溶解所述挥发油再喷入，混匀，即得颗粒剂。本发明通过合理的工艺筛选，经提取制成颗粒剂，疗效与原剂型一致。另外，通过本发明所获得的蒙药苏龙嘎‑4颗粒剂特别适用于儿童患者。
Description
技术领域
本发明涉及一种蒙药成方新剂型的制备方法，具体涉及一种蒙药苏龙嘎-4的制备方法。
背景技术
中华人民共和国卫生部制定药品标准蒙药分册(1998：106页)记载有苏龙嘎-4原剂型为药材直接粉碎、过筛、包装形成，口服原剂型，味苦涩、糊口、量大，有效活性成分难以完全溶出，影响药效的稳定性，特别对儿童患者尤为突出，是传统的汤剂。
发明内容
鉴于上述现有技术中所存在的问题，本发明提供一种蒙药苏龙嘎-4制备方法，克服了原剂型味苦涩、量大、糊口等问题。
具体技术方案如下：
一种蒙药苏龙嘎-4制备方法，蒙药苏龙嘎-4处方包括连翘、拳参、木通、麦冬，该制备方法包括如下步骤：
A.取连翘捣碎，加水，蒸馏法提取挥发油，挥发油备用，所述挥发油的提取时间为3～6小时；
B.连翘水溶液药渣与其余拳参、木通、麦冬三味药混合，水煎1-3次，合并过滤，滤液浓缩得浸膏，低温干燥，粉碎，加入矫味剂和糊精，制成颗粒，干燥；
C.加入所述挥发油或用有机溶剂溶解所述挥发油再喷入，混匀，即得颗粒剂。
在上述技术方案的基础上，还可增加以下技术特征进行进一步限定：
优选地，所述矫味剂的加入量为提取药粉重量的1～3％。
优选地，所述矫味剂选自蔗糖、甜蜜素、蛋白糖、甜菊素、阿司帕坦中的一种或多种。
优选地，所述糊精的加入量与提取药粉的重量比例为0.5～1.5：1。
优选地，在步骤B中，水煎1-3次，时间为各1～1.5小时。
优选地，在步骤B中，滤液浓缩至浸膏在50℃时的相对密度为1.3～1.6g/cm3。
优选地，在步骤B中，采用减压浓缩设备进行浓缩，温度控制在80℃以下。
优选地，在步骤B中，所述浸膏在95℃以下进行干燥。
本发明的有益效果如下：
本发明通过合理的工艺筛选，经提取制成颗粒剂，疗效与原剂型一致。另外，通过本发明所获得的蒙药苏龙嘎-4颗粒剂特别适用于儿童患者。
附图说明
图1示出了本发明的一个具体实施例的工艺流程图。
具体实施方式
下面结合附图和具体实例对本发明进行详细说明。
(1)本发明的工艺筛选过程如下：
①剂型确定
苏龙嘎-4原剂型为汤散剂，用于肠热、痢疾、腹痛、腹泻。由于是汤散剂味苦涩小儿拒绝吃药。经试验，原剂型提取后加适量糊精、矫味剂制成颗粒剂，口感改善，服用方便。
②工艺路线的确定
苏龙嘎-4颗粒剂的工艺路线是根据处方药物组成，所含有效成分的理化性质、生产实际等多方面因素，经反复试验研究、分析、比较而确定的。
连翘具有含多种活性成分，可做检测成分挥发油、连翘苷、连翘酯苷A等，拳参含有没食子酸、绿原酸，木通有原儿茶酸，麦冬有麦冬皂苷、麦冬黄酮。以上检测成分有较好的水溶性。从而确定苏龙嘎-4颗粒剂的基本工艺路线为加水提取，制成颗粒剂。
③水提条件考察
a连翘用水蒸气蒸馏法
经测定挥发油3h之前提取率高，之后提取率明显降低，6h后挥发油提尽。因此，挥发油的最佳提取时间为3～6小时。
表1连翘挥发油提取时间考察
b拳参、木通、麦冬水提工艺
表2因素水平
c试验方法
用正交试验对表2各因素进行考察，以绿原酸含量、浸膏率为考察指标，以权重系数计算综合评分。30/浸膏最大提取率×浸膏提取率，70/绿原酸最高提取率×绿原酸提取率(权重系数：浸膏0.3，绿原酸0.7)。
影响提取工艺影响因素：加水量>提取次数>浸泡时间>提取时间。综合评分方差分析结果：
A3B1C3D2(加12倍水，每次提取1h，提取3次，浸泡24h)
A2B1C2D3(加10倍水，每次提取1h，提取2次，浸泡48h)
A2B3C1D2(加10倍水，每次提取2h，提取1次，浸泡24h)
A2B2C3D1(加10倍水，每次提取1.5h，提取3次，浸泡12h)
依据上述分析，对提取工艺选择有利于工业化生产、降低成本因素搭配，即A2B2C2D2(加10倍水，每次提取1.5h，提取2次，浸泡24h)为最佳因素提取工艺。
d最佳提取工艺验证
称取连翘480g，提取挥发油，药渣与拳参420g、木通420g、麦冬300g混合，加10倍水，浸泡24h，每次提取1.5h，提取2次。依法测定绿原酸含量、浸膏提取率。绿原酸含量0.102％，浸膏提取率21.5％，与正交试验结果基本一致，说明该工艺条件基本稳定、合理。
表3L9(34)表及试验结果
表4方差分析
临界值F1-0.1(2，2)＝9F1-0.05(2，2)＝19.以B因素离差作为误差，检验因素的显著性,方差分析。
④浓缩、干燥、粉碎
为防止有效成分长时间受热破坏，本工艺采用减压浓缩设备进行浓缩，温度控制在80℃以下，浓缩至浸膏比重1.4～1.5(50℃)，浸膏在95℃以下进行干燥。
表5水提浸膏收率及出粉率
⑤辅料的筛选
矫味剂选择：以蔗糖、甜蜜素、蛋白糖、甜菊素、阿司帕坦作为矫味剂，考察矫味效果。蛋白糖、阿司帕坦矫味效果好，进一步考察，阿司帕坦2：100矫味效果比较好。
表6甜味素用量试验(g)
注 –口感差 +口感一般 ++口感好
糊精、乙醇：试验不同比例糊精用量及湿润剂乙醇浓度，以制粒是否粘筛、颗粒均匀性、成粒率及颗粒休止角为指标综合考察，最终选定糊精用量为药粉与糊精1：1；乙醇浓度75％。制成的颗粒粒度均匀，成粒率高、硬度适宜、溶化性好。
表7制粒成粒率、休止角
⑥服用量的确定
连翘727g、拳参636g、木通636g、麦冬455g(合计2454g)，出膏490-510g(膏-药材1︰5)，加490-510g糊精，矫味剂20g，合计成品1000g。每2g颗粒剂相当于药材5g，原剂型服5g，颗粒剂服2g。
(2)中试资料
结果表明，苏龙嘎-4颗粒剂装量、粒度、绿原酸含量、水份、微生物限度检查均符合要求，工艺稳定、可行，适合工业生产。
表8苏龙嘎-4颗粒剂中试生产数据
综上所述，本发明经过了深入工艺确定，确定了最佳的工艺过程和参数，且获得的颗粒剂疗效和口服感均佳，值得推广。
Claims (9)
1.一种蒙药苏龙嘎-4的制备方法，蒙药苏龙嘎-4处方包括连翘、拳参、木通、麦冬，其特征在于：
A.取连翘捣碎，加水，蒸馏法提取挥发油，挥发油备用,所述挥发油的提取时间为3～6小时；
B.连翘水溶液药渣与其余拳参、木通、麦冬三味药混合，加水浸泡，水煎1-3次，合并过滤，滤液浓缩得浸膏，低温干燥，粉碎，加入矫味剂和糊精，制成颗粒，干燥；
C.加入所述挥发油或用有机溶剂溶解所述挥发油再喷入，混匀，即得颗粒剂。
2.根据权利要求1所述的蒙药苏龙嘎-4的制备方法，其特征在于：所述矫味剂的加入量为步骤B中粉碎获得的提取药粉重量的1～3％。
3.根据权利要求1或2任一所述的蒙药苏龙嘎-4的制备方法，其特征在于：所述矫味剂选自蔗糖、甜蜜素、甜菊素、阿司帕坦中的一种或多种。
4.根据权利要求1所述的蒙药苏龙嘎-4的制备方法，其特征在于：所述糊精的加入量与步骤B中粉碎获得的提取药粉的重量比例为0.5～1.5：1。
5.根据权利要求1所述的蒙药苏龙嘎-4的制备方法，其特征在于：在步骤B中，水煎2次，时间各为1～1.5小时。
6.根据权利要求1所述的蒙药苏龙嘎-4的制备方法，其特征在于：所述连翘水溶液药渣与其余拳参、木通、麦冬三味药混合后的加水量为10-12倍。
7.根据权利要求1所述的蒙药苏龙嘎-4的制备方法，其特征在于：在步骤B中，滤液浓缩至浸膏比重为在50℃时的相对密度为1.3～1.6g/cm3。
8.根据权利要求1所述的蒙药苏龙嘎-4的制备方法，其特征在于：在步骤B中，采用减压浓缩设备进行浓缩，温度控制在80℃以下。
9.根据权利要求1所述的蒙药苏龙嘎-4的制备方法，其特征在于：在步骤B中，所述浸膏在95℃以下进行干燥。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810130334.9A CN108114149B (zh) | 2018-02-08 | 2018-02-08 | 一种蒙药苏龙嘎-4的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810130334.9A CN108114149B (zh) | 2018-02-08 | 2018-02-08 | 一种蒙药苏龙嘎-4的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108114149A CN108114149A (zh) | 2018-06-05 |
| CN108114149B true CN108114149B (zh) | 2020-11-17 |
Family
ID=62233463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810130334.9A Active CN108114149B (zh) | 2018-02-08 | 2018-02-08 | 一种蒙药苏龙嘎-4的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108114149B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110279798A (zh) * | 2019-07-10 | 2019-09-27 | 内蒙古民族大学 | 一种蒙药组合物及其制剂和用途 |
| CN111568996A (zh) * | 2020-06-17 | 2020-08-25 | 中央民族大学 | 一种蒙药组合物及其用途 |
| CN116139219A (zh) * | 2023-02-15 | 2023-05-23 | 内蒙古科技大学包头医学院 | 一种蒙药制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103330824A (zh) * | 2013-06-18 | 2013-10-02 | 内蒙古民族大学 | 一种治疗肝损伤的蒙药 |
-
2018
- 2018-02-08 CN CN201810130334.9A patent/CN108114149B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108114149A (zh) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108114149B (zh) | 一种蒙药苏龙嘎-4的制备方法 | |
| WO2017032285A1 (zh) | 一种参苓白术颗粒及其制备方法 | |
| WO2009117953A1 (zh) | 一种具有抗抑郁、抗焦虑作用的药物组合物及其制备方法 | |
| CN103356801B (zh) | 低温连续提取结合膜分离技术制备八珍颗粒的方法 | |
| CN111467451B (zh) | 一种治疗新型冠状病毒肺炎的组合物、制剂及其应用 | |
| CN113018405B (zh) | 一种治疗脑卒中后抑郁症的中药组合物及制备方法 | |
| CN102120015A (zh) | 一种用于舒肝解郁、安神定志的中药及制法和质量标准 | |
| CN1919272B (zh) | 一种中药浓缩丸 | |
| CN104489647A (zh) | 一种含黄芪、杜仲、黄精、沙棘、人参的抗疲劳保健食品及其制备方法 | |
| CN115944667B (zh) | 一种苓桂术甘汤提取物及其制备方法 | |
| CN107412462B (zh) | 一种黄龙咳喘胶囊的制备方法 | |
| CN114887024A (zh) | 一种治疗冠心病的中药组合物及其制备方法 | |
| CN1857608B (zh) | 老年咳喘胶囊的制备方法 | |
| CN104001014A (zh) | 一种川贝清肺糖浆及其生产工艺 | |
| CN105797092B (zh) | 益元抗感合剂 | |
| CN111803576A (zh) | 一种治疗痛风的复方六月雪胶囊 | |
| CN107952012A (zh) | 一种防治球虫病的中药组合物及其制备方法 | |
| CN117045744B (zh) | 一种补气健脾和/或化痰散结的中药组合物及其制备方法和用途 | |
| CN108969567B (zh) | 一种荡石中药组合物的制备方法 | |
| CN107970297A (zh) | 一种镇静安神的药物 | |
| CN109157632B (zh) | 一种治疗胃脘痛颗粒剂配方及制备方法 | |
| CN106511500A (zh) | 一种治疗妇科疾病组合物、含有该组合物的药剂及其制备方法 | |
| CN100518758C (zh) | 参坤养血颗粒及其制备 | |
| CN106692089B (zh) | 一种妇炎舒片剂及其制备方法 | |
| CN105168160A (zh) | 一种羚羊感冒片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |